Shu Chin

Shu Chin Ma has a strong background in pharmacometrics, clinical pharmacology, and development, with expertise in areas such as rare diseases, oncology, and gene therapies. They have held key positions in various organizations, including Critical Path Institute (C-Path), PTC Therapeutics, Inc., BioCryst Pharmaceuticals, Inc., Ascentage Pharma, Certara, FDA, Auckland University of Technology, Auckland UniServices Limited, University of Auckland, and Nova Eco-Tech. Shu Chin Ma has a track record of successfully leading teams, contributing technical expertise, and facilitating collaborations. They have demonstrated exceptional leadership, strategic insight, and valuable contributions in the areas of modelling and statistical analysis plans, regulatory endorsement, filing plans, data management and analysis, and project management. Shu Chin Ma has also contributed to teaching and mentorship in academic settings.

Shu Chin Ma has a diverse education history. Shu Chin completed their Bachelor of Science degree in Medicine from the University of Otago between 1993 and 1995. Shu Chin then pursued a Bachelor of Engineering degree in Chemicals & Materials Engineering at The University of Auckland, completing it with first-class honors between 1996 and 1998. Moving on to graduate studies, they earned a Master of Science degree in Biomedical Engineering from Cornell University from 1999 to 2002. Following that, they obtained both a Master of Philosophy and a Doctor of Philosophy degree in Biomedical Engineering from Yale University from 2002 to 2004.

In terms of additional certifications, Shu Chin Ma completed the PRINCE2 Project Management Practitioner course in August 2011. Shu Chin also obtained certifications in Clinical Research Training, Good Clinical Practice from two different institutions, and Introduction to the Clinical Drug Development Process: ICH/FDA GCP. Additionally, they completed courses in pharmaceutical bioinformatics from Uppsala University and clinical pharmacology from The University of Auckland.

Most recently, they pursued an Executive MBA from the Quantic School of Business and Technology between 2019 and 2020.